Rankings
▼
Calendar
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$60M
Net Income
-$59M
EPS (Diluted)
$-3.82
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$55M
Free Cash Flow
-$55M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$287M
Total Liabilities
$47M
Stockholders' Equity
$240M
Cash & Equivalents
$54M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$60M
-$30M
-98.8%
Net Income
-$59M
-$28M
-113.1%
← FY 2020
All Quarters
Q1 2021 →
MDGL Q4 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena